Pioglitazone attenuates progression of aortic valve calcification via down-regulating Receptor for advanced glycation end products

Basic Research in Cardiology

Volumn 107, Issue 6, 2012, Pages

  Li, Fei ^a   Cai, Zhejun ^a,b   Chen, Fang ^c   Shi, Xucong ^a   Zhang, Qiao ^a   Chen, Si ^a   Shi, Jiawei ^a   Wang, Dao Wen ^a   Dong, Nianguo ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Aortic valve calcification; Inflammation; Osteoblastic differentiation; Pioglitazone; Receptor for advanced glycation end products; Valvular interstitial cells

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; BOVINE SERUM ALBUMIN; CHOLESTEROL; ERGOCALCIFEROL; OSTEOPONTIN; PIOGLITAZONE; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA VALVE CALCIFICATION; AORTA VALVE DISEASE; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; ECHOCARDIOGRAPHY; GENE SILENCING; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; INFLAMMATION; INFLAMMATORY CELL; MALE; NONHUMAN; OSTEOBLAST; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN EXPRESSION; RABBIT; RECEPTOR DOWN REGULATION; SWINE;

EID: 85027958993     PISSN: 03008428     EISSN: 14351803     Source Type: Journal    
DOI: 10.1007/s00395-012-0306-01     Document Type: Article

References (51)

1. -/- mice. Arterioscler Thromb Vasc Biol 27:2589-2596. doi: 10.1161/ATVBAHA.107.153668 (Pubitemid 350158910)
2. Basta G, Corciu AI, Vianello A, Del Turco S, Foffa I, Navarra T, Chiappino D, Berti S, Mazzone A (2010) Circulating soluble receptor for advanced glycation end-product levels are decreased in patients with calcific aortic valve stenosis. Atherosclerosis 210:614-618. doi:10.1016/j.atherosclerosis.2009. 12.029
3. Beckmann E, Grau JB, Sainger R, Poggio P, Ferrari G (2010) Insights into the use of biomarkers in calcific aortic valve disease. J Heart Valve Dis 19:441-452
4. Birnbaum Y, Long B, Qian J, Perez-Polo JR, Ye Y (2011) Pioglitazone limits myocardial infarct size, activates Akt, and upregulates cPLA2 and COX-2 in a PPAR-gamma-independent manner. Basic Res Cardiol 106:431-446. doi:10.1007/s00395-011-0162-3
5. Bonow RO, Carabello BA, Chatterjee K, De Leon AC Jr, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'Gara PT, O'Rourke RA, Otto CM, Shah PM, Shanewise JS (2008) 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American college of Cardiology/American heart association task force on practice guidelines (writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease): endorsed by the society of cardiovascular anesthesiologists, society for cardiovascular angiography and interventions, and society of thoracic surgeons. Circulation 118:e523-e661. doi:10.1161/CIRCULATIONAHA. 108.190748
6. Brett J, Schmidt AM, Yan SD, Zou YS, Weidman E, Pinsky D, Nowygrod R, Neeper M, Przysiecki C, Shaw A, Migheli A, Stern D (1993) Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 143:1699-1712 (Pubitemid 24058273)
7. Cai Z, Li F, Peng C, Li H, Zong Y, Liu Z, Qu S (2010) Effect of insulin on the differential expression of VLDL receptor isoforms of SGC7901 cell and its biological implication. J Huazhong Univ Sci Technol Med Sci 30:551-555. doi:10.1007/s11596-010-0541-2
8. -/- mice. J Vasc Res 48:227-235. doi:10.1159/000318805
9. Chavakis T, Bierhaus A, Nawroth PP (2004) RAGE (receptor for advanced glycation end products): a central player in the inflammatory response. Microbes Infect 6:1219-1225. doi:10.1016/j.micinf.2004.08.004 (Pubitemid 39370091)
10. Drolet MC, Arsenault M, Couet J (2003) Experimental aortic valve stenosis in rabbits. J Am Coll Cardiol 41:1211-1217 (Pubitemid 36384911)
11. Gallagher AM, Smeeth L, Seabroke S, Leufkens HG, van Staa TP (2011) Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data. PLoS ONE 6:e28157. doi:10.1371/journal.pone.0028157
12. Hanefeld M, Pfutzner A, Forst T, Kleine I, Fuchs W (2011) Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study. Cardiovasc Diabetol 10:65. doi:10.1186/1475-2840-10-65
13. -/- mice. J Clin Invest 118:183-194. doi:10.1172/JCI32703
14. Helske S, Lindstedt KA, Laine M, Mayranpaa M, Werkkala K, Lommi J, Turto H, Kupari M, Kovanen PT (2004) Induction of local angiotensin II-producing systems in stenotic aortic valves. J Am Coll Cardiol 44:1859-1866. doi:10.1016/j.jacc.2004.07.054 (Pubitemid 39424087)
15. Hernandez AV, Usmani A, Rajamanickam A, Moheet A (2011) Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and metaregression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs 11:115-128. doi:10.2165/11587580-000000000-00000
16. Hofmann Bowman MA, Gawdzik J, Bukhari U, Husain AN, Toth PT, Kim G, Earley J, McNally EM (2011) S100A12 in vascular smooth muscle accelerates vascular calcification in apolipoprotein E-null mice by activating an osteogenic gene regulatory program. Arterioscler Thromb Vasc Biol 31:337-344. doi:10.1161/ATVBAHA.110.217745
17. Hsueh WA, Bruemmer D (2004) Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease. Hypertension 43:297-305. doi:10.1161/01. HYP.0000113626. 76571.5b (Pubitemid 38174129)
18. Ihm SH, Chang K, Kim HY, Baek SH, Youn HJ, Seung KB, Kim JH (2010) Peroxisome proliferator-activated receptor-gamma activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth factor. Basic Res Cardiol 105:399-407. doi:10.1007/s00395-009- 0071-x
19. Johnson CM, Hanson MN, Helgeson SC (1987) Porcine cardiac valvular subendothelial cells in culture: cell isolation and growth characteristics. J Mol Cell Cardiol 19:1185-1193
20. Joner M, Farb A, Cheng Q, Finn AV, Acampado E, Burke AP, Skorija K, Creighton W, Kolodgie FD, Gold HK, Virmani R (2007) Pioglitazone inhibits in-stent restenosis in atherosclerotic rabbits by targeting transforming growth factor-beta and MCP-1. Arterioscler Thromb Vasc Biol 27:182-189. doi:10.1161/01. ATV.0000251021.28725.e8 (Pubitemid 46360397)
21. Kaden JJ, Bickelhaupt S, Grobholz R, Vahl CF, Hagl S, Brueckmann M, Haase KK, Dempfle CE, Borggrefe M (2004) Expression of bone sialoprotein and bone morphogenetic protein-2 in calcific aortic stenosis. J Heart Valve Dis 13:560-566
22. Kaden JJ, Dempfle CE, Grobholz R, Fischer CS, Vocke DC, Kilic R, Sarikoc A, Pinol R, Hagl S, Lang S, Brueckmann M, Borggrefe M (2005) Inflammatory regulation of extracellular matrix remodeling in calcific aortic valve stenosis. Cardiovasc Pathol 14:80-87. doi:10.1016/j.carpath.2005.01.002 (Pubitemid 40381303)
23. Kaden JJ, Dempfle CE, Grobholz R, Tran HT, Kilic R, Sarikoc A, Brueckmann M, Vahl C, Hagl S, Haase KK, Borggrefe M (2003) Interleukin-1 beta promotes matrix metalloproteinase expression and cell proliferation in calcific aortic valve stenosis. Atherosclerosis 170:205-211 (Pubitemid 37377791)
24. Katz R, Budoff MJ, Takasu J, Shavelle DM, Bertoni A, Blumenthal RS, Ouyang P, Wong ND, O'Brien KD (2009) Relationship of metabolic syndrome with incident aortic valve calcium and aortic valve calcium progression: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes 58:813-819. doi: 10.2337/db08-1515
25. Liberman M, Bassi E, Martinatti MK, Lario FC, Wosniak J Jr, Pomerantzeff PM, Laurindo FR (2008) Oxidant generation predominates around calcifying foci and enhances progression of aortic valve calcification. Arterioscler Thromb Vasc Biol 28:463-470. doi:10.1161/ATVBAHA.107.156745
26. Lin L (2006) RAGE on the Toll Road? Cell Mol Immunol 3:351-358
27. Lin L, Park S, Lakatta EG (2009) RAGE signaling in inflammation and arterial aging. Front Biosci 14:1403-1413
28. Loke YK, Kwok CS, Singh S (2011) Comparative cardiovascular effects of thiazolidinediones: systematic reviewandmeta-analysis of observational studies. BMJ 342:d1309. doi:10.1136/bmj.d1309
29. Lu Y, Qin W, Shen T, Dou L, Man Y, Wang S, Xiao C, Li J (2011) The antioxidant N-acetylcysteine promotes atherosclerotic plaque stabilization through suppression of RAGE, MMPs and NF-kappaB in ApoE-deficient mice. J Atheroscler Thromb 18:998-1008
30. Maniati E, Bossard M, Cook N, Candido JB, Emami-Shahri N, Nedospasov SA, Balkwill FR, Tuveson DA, Hagemann T (2011) Crosstalk between the canonical NF-kappaB and Notch signaling pathways inhibits Ppargamma expression and promotes pancreatic cancer progression in mice. J Clin Invest 121:4685-4699. doi:10.1172/JCI45797
31. Marx N, Walcher D, Ivanova N, Rautzenberg K, Jung A, Friedl R, Hombach V, de Caterina R, Basta G, Wautier MP, Wautiers JL (2004) Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products. Diabetes 53:2662-2668 (Pubitemid 39299276)
32. Nagy E, Andersson DC, Caidahl K, Eriksson MJ, Eriksson P, Franco-Cereceda A, Hansson GK, Back M (2011) Upregulation of the 5-lipoxygenase pathway in human aortic valves correlates with severity of stenosis and leads to leukotriene-induced effects on valvular myofibroblasts. Circulation 123:1316-1325. doi: 10.1161/CIRCULATIONAHA.110.966846
33. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A (1992) Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267:14998-15004
34. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M (2006) Burden of valvular heart diseases: a population-based study. Lancet 368:1005-1011. doi:10.1016/S0140-6736 (06) 69208-8 (Pubitemid 44353666)
35. O'Brien KD (2006) Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more). Arterioscler Thromb Vasc Biol 26:1721-1728. doi:10.1161/01. ATV.0000227513.13697.ac (Pubitemid 44305324)
36. Olsson M, Dalsgaard CJ, Haegerstrand A, Rosenqvist M, Ryden L, Nilsson J (1994) Accumulation of T lymphocytes and expression of interleukin-2 receptors in nonrheumatic stenotic aortic valves. J Am Coll Cardiol 23:1162-1170 (Pubitemid 24117151)
37. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD (1994) Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 90:844-853 (Pubitemid 24242754)
38. Prince M, Banerjee C, Javed A, Green J, Lian JB, Stein GS, Bodine PV, Komm BS (2001) Expression and regulation of Runx2/Cbfa1 and osteoblast phenotypic markers during the growth and differentiation of human osteoblasts. J Cell Biochem 80:424-440. doi:10.1002/1097-4644 (20010301) 80:3<424 (Pubitemid 32141498)
39. Rajamannan NM, Evans FJ, Aikawa E, Grande-Allen KJ, Demer LL, Heistad DD, Simmons CA, Masters KS, Mathieu P, O'Brien KD, Schoen FJ, Towler DA, Yoganathan AP, Otto CM (2011) Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: calcific aortic valve disease-2011 update. Circulation 124:1783-1791. doi:10.1161/CIRCULATIONAHA.110.006767
40. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391:79-82. doi: 10.1038/34178 (Pubitemid 28079218)
41. Soro-Paavonen A, Watson AM, Li J, Paavonen K, Koitka A, Calkin AC, Barit D, Coughlan MT, Drew BG, Lancaster GI, Thomas M, Forbes JM, Nawroth PP, Bierhaus A, Cooper ME, Jandeleit-Dahm KA (2008) Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 57:2461-2469. doi:10.2337/db07-1808
42. Speidl WS, Cimmino G, Ibanez B, Elmariah S, Hutter R, Garcia MJ, Fuster V, Goldman ME, Badimon JJ (2010) Recombinant apolipoprotein A-I Milano rapidly reverses aortic valve stenosis and decreases leaflet inflammation in an experimental rabbit model. Eur Heart J 31:2049-2057. doi:10.1093/eurheartj/ ehq064
43. Suga T, Iso T, Shimizu T, Tanaka T, Yamagishi S, Takeuchi M, Imaizumi T, Kurabayashi M (2011) Activation of receptor for advanced glycation end products induces osteogenic differentiation of vascular smooth muscle cells. J Atheroscler Thromb 18:670-683
44. Sun L, Ishida T, Yasuda T, Kojima Y, Honjo T, Yamamoto Y, Yamamoto H, Ishibashi S, Hirata K, Hayashi Y (2009) RAGE mediates oxidized LDL-induced pro-inflammatory effects and atherosclerosis in non-diabetic LDL receptor-deficient mice. Cardiovasc Res 82:371-381. doi:10.1093/cvr/cvp036
45. Syvaranta S, Helske S, Laine M, Lappalainen J, Kupari M, Mayranpaa MI, Lindstedt KA, Kovanen PT (2010) Vascular endothelial growth factor-secreting mast cells and myofibroblasts: a novel self-perpetuating angiogenic pathway in aortic valve stenosis. Arterioscler Thromb Vasc Biol 30:1220-1227. doi:10.1161/ATVBAHA.109.198267
46. Tanikawa T, Okada Y, Tanikawa R, Tanaka Y (2009) Advanced glycation end products induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK. J Vasc Res 46:572-580. doi:10.1159/000226225
47. Volz HC, Laohachewin D, Seidel C, Lasitschka F, Keilbach K, Wienbrandt AR, Andrassy J, Bierhaus A, Kaya Z, Katus HA, Andrassy M (2012) S100A8/A9 aggravates post-ischemic heart failure through activation of RAGE-dependent NF-kappaB signaling. Basic Res Cardiol 107:250. doi:10.1007/s00395-012-0250-z
48. Volz HC, Seidel C, Laohachewin D, Kaya Z, Muller OJ, Pleger ST, Lasitschka F, Bianchi ME, Remppis A, Bierhaus A, Katus HA, Andrassy M (2010) HMGB1: the missing link between diabetes mellitus and heart failure. Basic Res Cardiol 105:805-820. doi:10.1007/s00395-010-0114-3
49. Wang K, Zhou Z, Zhang M, Fan L, Forudi F, Zhou X, Qu W, Lincoff AM, Schmidt AM, Topol EJ, Penn MS (2006) Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model. J Pharmacol Exp Ther 317:37-43. doi: 10.1124/jpet.105. 095125
50. Ye Y, Perez-Polo JR, Aguilar D, Birnbaum Y (2011) The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury. Basic Res Cardiol 106:925-952. doi:10.1007/s00395-011-0216-6
51. Yu Z, Seya K, Daitoku K, Motomura S, Fukuda I, Furukawa K (2011) Tumor necrosis factor-alpha accelerates the calcification of human aortic valve interstitial cells obtained from patients with calcific aortic valve stenosis via the BMP2-Dlx5 pathway. J Pharmacol Exp Ther 337:16-23. doi:10.1124/jpet.110. 177915